2015
CD25 (IL2RA) Orchestrates Negative Feedback Control and Stabilizes Oncogenic Signaling Strength in Acute Lymphoblastic Leukemia
Lee J, Chen Z, Geng H, Xiao G, Eugene P, Parekh S, Kornblau S, Melnick A, Abbas A, Paietta E, Muschen M. CD25 (IL2RA) Orchestrates Negative Feedback Control and Stabilizes Oncogenic Signaling Strength in Acute Lymphoblastic Leukemia. Blood 2015, 126: 1434. DOI: 10.1182/blood.v126.23.1434.1434.Peer-Reviewed Original ResearchPre-BCR signalingPre-B cell receptorCytoplasmic tailOncogenic tyrosine kinasesB cell developmentTyrosine kinaseSerine/threonine protein kinaseCell developmentConstitutive membrane localizationCytoplasmic interaction partnersReceptor chainsEarly B cell developmentThreonine protein kinaseDownstream tyrosine kinasePre-B cell stageShort cytoplasmic tailNegative feedback controlComprehensive gene expression analysisDependent signal transductionTyrosine kinase BtkTyrosine kinase oncogenesGene expression analysisSerial transplantation experimentsB lineage cellsAbsence of CD25
2010
Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia
Fei F, Stoddart S, Müschen M, Kim Y, Groffen J, Heisterkamp N. Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia. Leukemia 2010, 24: 813-820. PMID: 20111071, PMCID: PMC3038787, DOI: 10.1038/leu.2009.302.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsApoptosisBlotting, WesternCells, CulturedDasatinibDrug Resistance, NeoplasmEmbryo, MammalianFibroblastsFusion Proteins, bcr-ablHumansLeukemia, ExperimentalMiceMice, Inbred NODMice, KnockoutMice, SCIDPhosphorylationPrecursor Cell Lymphoblastic Leukemia-LymphomaProtein Kinase InhibitorsProtein-Tyrosine KinasesPyrimidinesReceptors, CXCR4Src-Family KinasesStromal CellsThiazolesConceptsLong-term treatmentBcr/Abl-positive acute lymphoblastic leukemiaPhiladelphia chromosome-positive leukemiaAcute lymphoblastic leukemia cellsLeukemia cellsTreatment of miceAcute lymphoblastic leukemiaEffects of dasatinibLymphoblastic leukemia cellsTyrosine kinase inhibitionDrug-resistant cellsHigh-dose pulseBCR/ABLDasatinib monotherapyDaily doseDevelopment of resistanceDasatinib treatmentLymphoblastic leukemiaB lineage cellsCell surface expressionCXCR4 inhibitorsEnhanced cell deathLow doseLow dosesDasatinib